Aura Biosciences, Inc.

AURA

$192M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaBOSTON106 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 31, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

AU-011 Phase 2 Results Expected

Mar 31, 2026AU-01124

Primary completion for AU-011 trial (NCT06643884) in Eye Cancer

Source

Phase 2

AU-011 Phase 2 Results Expected

Nov 30, 2026AU-01124

Primary completion for AU-011 trial (NCT06643884) in Eye Cancer

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Bel-sar

Phase 3

Choroidal Melanoma

Light-activated AU-011

Phase 2

Uveal Melanoma

AU-011

Phase 2

Eye Cancer

Drug Name	Phase	Indication	Designations
Bel-sar	Phase 3	Choroidal Melanoma	-
Light-activated AU-011	Phase 2	Uveal Melanoma	-
AU-011	Phase 2	Eye Cancer	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

AURA News